A股異動丨 Q4業績大超預期 同花順(300033.SZ)大幅拉昇近14%
格隆匯2月1日丨受盈喜消息影響,同花順(300033.SZ)今日大幅高開,現漲幅擴大至13.66%,報135.02元,成交額放大至10.8億元,總市值725.87億元。同花順1月29日公吿,預計2020年淨利潤16.2億元-18億元,同比增長80%-100%;實現扣非歸母淨利潤15.0-16.7 億元,預計同比增長80%-100%。公司3Q20歸母淨利潤為7.7億元,同比增長68.5%。天風證券估算Q4單季實現淨利潤8.4-10.2億元,同比增長91.8%-132.6%,大超市場預期。國盛證券維持同花順“買入”評級。根據關鍵假設及近期財報,上調盈利預測。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.